| Year |
Citation |
Score |
| 2024 |
van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, et al. Author Correction: Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering. PMID 38347164 DOI: 10.1038/s41551-024-01181-y |
0.345 |
|
| 2023 |
Hammer Q, Perica K, van Ooijen H, Mbofung R, Momayyezi P, Varady E, Martin KE, Pan Y, Jelcic M, Groff B, Abujarour R, Krokeide S, Lee T, Williams A, Goodridge JP, et al. Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells. Biorxiv : the Preprint Server For Biology. PMID 37873468 DOI: 10.1101/2023.10.09.557143 |
0.319 |
|
| 2022 |
Cichocki F, Bjordahl R, Goodridge JP, Mahmood S, Gaidarova S, Abujarour R, Davis ZB, Merino A, Tuininga K, Wang H, Kumar A, Groff B, Witty A, Bonello G, Huffman J, et al. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. Nature Communications. 13: 7341. PMID 36446823 DOI: 10.1038/s41467-022-35127-2 |
0.332 |
|
| 2022 |
van der Stegen SJC, Lindenbergh PL, Petrovic RM, Xie H, Diop MP, Alexeeva V, Shi Y, Mansilla-Soto J, Hamieh M, Eyquem J, Cabriolu A, Wang X, Abujarour R, Lee T, Clarke R, et al. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering. PMID 35941192 DOI: 10.1038/s41551-022-00915-0 |
0.337 |
|
| 2021 |
Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, Tuininga K, Zhang B, Wu CY, Kodal B, Khaw M, et al. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell Stem Cell. PMID 34525347 DOI: 10.1016/j.stem.2021.08.013 |
0.368 |
|
| 2020 |
Mandal M, Clarke R, Stegen Svd, Chang C, Lai Y, Witty A, Husain M, Wu C, Yang B, Dufaud C, Hsia G, Shaked H, Stokely L, Chu H, Pribadi M, ... ... Abujarour R, et al. Abstract 3245: FT819 path to IND: First-of-kind off-the-shelf CAR19 T-cell for B cell malignancies Immunology. DOI: 10.1158/1538-7445.Am2020-3245 |
0.359 |
|
| 2019 |
Zhu H, Blum R, Bjordahl R, Gaidarova S, Rogers P, Lee TT, Abujarour R, Bonello GB, Wu J, Tsai PF, Miller JS, Walcheck B, Valamehr B, Kaufman DS. Pluripotent stem cell-derived NK cells with high-affinity non-cleavable CD16a mediate improved anti-tumor activity. Blood. PMID 31856277 DOI: 10.1182/Blood.2019000621 |
0.508 |
|
| 2019 |
Bjordahl R, Gaidarova S, Goodridge JP, Mahmood S, Bonello G, Robinson M, Ruller C, Pribadi M, Lee T, Abujarour R, Dinella J, Huffman J, Chu H, Hopken U, Rehm A, et al. FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma Blood. 134: 3214-3214. DOI: 10.1182/Blood-2019-131373 |
0.308 |
|
| 2019 |
Chang C, Van Der Stegen S, Mili M, Clarke R, Lai Y, Witty A, Lindenbergh P, Yang B, Husain M, Shaked H, Groff B, Stokely L, Abujarour R, Lee T, Chu H, et al. FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial Blood. 134: 4434-4434. DOI: 10.1182/Blood-2019-130584 |
0.434 |
|
| 2019 |
Abujarour R, Lai Y, Pribadi M, Lee T, Robinson M, Ruller C, Stegen SVd, Wang X, Stefanski J, Zhen J, Dinella J, Bonello G, Huffman J, Chu H, Clarke R, et al. Abstract LB-073: Generation of novel single cell-derived engineered master pluripotent cell line as a renewable source for off-the-shelf TCR-less CAR T cells in support of first-of-kind clinical trial Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-073 |
0.478 |
|
| 2019 |
Bjordahl R, Zhu H, Rogers P, Gaidarova S, Ge MQ, Blum R, Cichocki F, Goodridge J, Chu H, Bonello G, Lee T, Groff B, Abujarour R, Walcheck B, Miller J, et al. Abstract 3191: FT516, an off-the-shelf engineered NK cell therapeutic product for universal anti-tumor targeting strategy in combination with monoclonal antibodies Cancer Research. 79: 3191-3191. DOI: 10.1158/1538-7445.Am2019-3191 |
0.425 |
|
| 2018 |
Clarke R, Van Der Stegen S, Chang C, Husain M, Lai Y, Peralta E, Stokely L, Abujarour R, Dinella J, Lee T, Pribadi M, Chu H, Truong C, Sabouri-Ghomi M, Meza M, et al. Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies Blood. 132: 4546-4546. DOI: 10.1182/Blood-2018-99-116843 |
0.414 |
|
| 2018 |
Bjordahl R, Mahmood S, Gaidarova S, Abujarour R, Clarke R, Stokely L, Rogers P, Ge M, Robinson M, Rezner B, Lee TT, Valamehr B. Abstract 3576: FT500, an off-the-shelf NK cell cancer immunotherapy derived from a master pluripotent cell line, enhances T-cell activation and recruitment to overcome checkpoint blockade resistance Cancer Research. 78: 3576-3576. DOI: 10.1158/1538-7445.Am2018-3576 |
0.381 |
|
| 2017 |
Cichocki F, Bjordahl R, Gaidarova S, Rogers P, Clarke R, Groff B, Moreno S, Abujarour R, Robinson M, Bonello G, Lee T, Lan W, Rezner B, Abbot S, Sumstad D, et al. Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Blood. 130: 656-656. DOI: 10.1182/Blood.V130.Suppl_1.656.656 |
0.509 |
|
| 2017 |
Bjordahl R, Clarke R, Gaidarova S, Bauer M, Sasaki J, Groff B, Lee T, Lan W, Abujarour R, Bonello G, Robinson M, Hardy I, Shoemaker D, Valamehr B. Multi-Functional Genetic Engineering of Pluripotent Cell Lines for Universal Off-the-Shelf Natural Killer Cell Cancer Immunotherapy Blood. 130: 3187-3187. DOI: 10.1182/Blood.V130.Suppl_1.3187.3187 |
0.505 |
|
| 2017 |
Bjordahl R, Cichocki F, Clarke R, Gaidarova S, Groff B, Rogers P, Moreno S, Abujarour R, Bonello G, Lee T, Lan W, Bauer M, Robbins D, Rezner B, Cooley S, et al. Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy Cancer Research. 77: 3755-3755. DOI: 10.1158/1538-7445.Am2017-3755 |
0.428 |
|
| 2016 |
Abujarour R, Lan W, Lee TT, Bonello G, Meza M, Robinson M, Clarke R, Truong C, Lynn C, Robbins D, Rezner B, Abbot SE, Shoemaker D, Valamehr B. Efficient Site-Specific Multi-Gene Engineering of Renewable Pluripotent Cells for Generation of Off-the-Shelf Hematopoietic Immunotherapeutics Blood. 128: 5887-5887. DOI: 10.1182/Blood.V128.22.5887.5887 |
0.512 |
|
| 2016 |
Bjordahl R, Clarke R, Gaidarova S, Groff B, Rogers P, Moreno S, Abujarour R, Bonello G, Lee TT, Lan W, Burrascano M, Bauer M, Robinson M, Sasaki J, Kim W, et al. Off-the-Shelf Natural Killer Cell Immunotherapy for Enhanced Antibody Directed Cellular Cytotoxicity Blood. 128: 3363-3363. DOI: 10.1182/Blood.V128.22.3363.3363 |
0.476 |
|
| 2016 |
Bauer M, Clarke R, Sasaki J, Groff B, Lee TT, Lan W, Abujarour R, Bonello G, Burrascano M, Robinson M, Bjordahl R, Gaidarova S, Abbot SE, Wolchko S, Shoemaker D, et al. Genetic Engineering of Pluripotent Cells for the Continuous Derivation of Off-the-Shelf Effector Lymphocytes with Enhanced Therapeutic Persistence By Overcoming the Host Histocompatibility Barrier Blood. 128: 2165-2165. DOI: 10.1182/Blood.V128.22.2165.2165 |
0.522 |
|
| 2016 |
Clarke R, Groff B, Sasaki J, Bauer M, Lee TT, Lan W, Burrascano M, Abujarour R, Bonello G, Robinson M, Foster H, Robbins D, Wolchko S, Shoemaker D, Abbot SE, et al. Genetically Enhanced Pluripotent Stem Cell-Derived T Lymphocytes for Off-the-Shelf Cellular Immunotherapy Blood. 128: 2164-2164. DOI: 10.1182/Blood.V128.22.2164.2164 |
0.525 |
|
| 2015 |
Abujarour R, Valamehr B. Generation of skeletal muscle cells from pluripotent stem cells: advances and challenges Frontiers in Cell and Developmental Biology. 3: 29-29. PMID 26029693 DOI: 10.3389/Fcell.2015.00029 |
0.574 |
|
| 2015 |
Huang X, Lan W, Parone P, Clarke R, Abujarour R, Robinson M, Meza M, Raynel S, Rezner B, Robbins D, Lee TT, Shoemaker D, Valamehr B. Human Induced Pluripotent Stem Cells Incorporating Safe Harbor Loci Integrated Inducible Suicide Systems for Use in the Application of Cellular Therapeutics Blood. 126: 3237-3237. DOI: 10.1182/Blood.V126.23.3237.3237 |
0.505 |
|
| 2015 |
Clarke R, Kim W, Groff B, Abujarour R, Robinson M, Huang X, Sahaf N, Raynel S, Rezner B, Robbins D, Guerrettaz L, Shoemaker D, Valamehr B. A Platform for the Scalable Derivation of Genetically-Enhanced T and NK Lymphocytes from Naive Human Induced Pluripotent Stem Cells for Cancer Immunotherapy Blood. 126: 2364-2364. DOI: 10.1182/Blood.V126.23.2364.2364 |
0.585 |
|
| 2014 |
Galasso M, Dama P, Previati M, Sandhu S, Palatini J, Coppola V, Warner S, Sana ME, Zanella R, Abujarour R, Desponts C, Teitell MA, Garzon R, Calin G, Croce CM, et al. A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. Genome Medicine. 6: 76. PMID 25352916 DOI: 10.1186/S13073-014-0076-4 |
0.731 |
|
| 2014 |
Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Garzon ME, Di Leva G, Gasparini P, Dama P, et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. Journal of the National Cancer Institute. 106. PMID 25306216 DOI: 10.1093/Jnci/Dju324 |
0.721 |
|
| 2014 |
Valamehr B, Robinson M, Abujarour R, Rezner B, Vranceanu F, Le T, Medcalf A, Lee TT, Fitch M, Robbins D, Flynn P. Platform for induction and maintenance of transgene-free hiPSCs resembling ground state pluripotent stem cells. Stem Cell Reports. 2: 366-81. PMID 24672758 DOI: 10.1016/J.Stemcr.2014.01.014 |
0.528 |
|
| 2014 |
Abujarour R, Bennett M, Valamehr B, Lee TT, Robinson M, Robbins D, Le T, Lai K, Flynn P. Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery. Stem Cells Translational Medicine. 3: 149-60. PMID 24396035 DOI: 10.5966/Sctm.2013-0095 |
0.548 |
|
| 2013 |
Abujarour R, Valamehr B, Robinson M, Rezner B, Vranceanu F, Flynn P. Optimized surface markers for the prospective isolation of high-quality hiPSCs using flow cytometry selection. Scientific Reports. 3: 1179. PMID 23378912 DOI: 10.1038/Srep01179 |
0.438 |
|
| 2012 |
Valamehr B, Abujarour R, Robinson M, Le T, Robbins D, Shoemaker D, Flynn P. A novel platform to enable the high-throughput derivation and characterization of feeder-free human iPSCs. Scientific Reports. 2: 213. PMID 22355727 DOI: 10.1038/Srep00213 |
0.565 |
|
| 2010 |
Abujarour R, Efe J, Ding S. Genome-wide gain-of-function screen identifies novel regulators of pluripotency. Stem Cells (Dayton, Ohio). 28: 1487-97. PMID 20629179 DOI: 10.1002/Stem.472 |
0.768 |
|
| 2010 |
Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, Ding S, Guan KL. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes & Development. 24: 1106-18. PMID 20516196 DOI: 10.1101/Gad.1903310 |
0.686 |
|
| 2009 |
Li W, Zhou H, Abujarour R, Zhu S, Young Joo J, Lin T, Hao E, Schöler HR, Hayek A, Ding S. Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells (Dayton, Ohio). 27: 2992-3000. PMID 19839055 DOI: 10.1002/Stem.240 |
0.746 |
|
| 2009 |
Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R, Lin X, Hahm HS, Hao E, Hayek A, Ding S. A chemical platform for improved induction of human iPSCs. Nature Methods. 6: 805-8. PMID 19838168 DOI: 10.1038/Nmeth.1393 |
0.591 |
|
| 2009 |
Abujarour R, Ding S. Induced pluripotent stem cells free of exogenous reprogramming factors. Genome Biology. 10: 220. PMID 19439061 DOI: 10.1186/Gb-2009-10-5-220 |
0.728 |
|
| 2005 |
Abujarour RJ, Dalal S, Hanson PI, Draper RK. p97 Is in a complex with cholera toxin and influences the transport of cholera toxin and related toxins to the cytoplasm. The Journal of Biological Chemistry. 280: 15865-71. PMID 15691847 DOI: 10.1074/Jbc.M406316200 |
0.586 |
|
| 2003 |
Chen A, AbuJarour RJ, Draper RK. Evidence that the transport of ricin to the cytoplasm is independent of both Rab6A and COPI. Journal of Cell Science. 116: 3503-10. PMID 12865434 DOI: 10.1242/Jcs.00641 |
0.655 |
|
| Show low-probability matches. |